US News

U.S. Supreme Court rejects J&J appeal over Risperdal drug

Published by

By Lawrence Hurley WASHINGTON (Reuters) – The U.S. Supreme Court rejected a bid by Johnson & Johnson to overturn a $70 million jury verdict against the pharmaceutical company for its failure to warn about risks associated with off-label uses of its antipsychotic drug Risperdal. The court turned away the company’s appeal of a November 2019 ruling by the Superior Court of Pennsylvania that upheld the verdict in favor of a Tennessee man named Adam Yount, who was prescribed the drug at age 4 in 2003. A jury in the Philadelphia Court of Common Pleas in 2016 found that the company failed to warn You…

Read More

Facebook Comments

Check Also

Demonstrations in Germany against Covid-19 rules, compulsory vaccines

Published by DPA Several thousand people protested in ...